Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Trevena

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London

              Contact the Supplier

              Lead Product(s): TRV027

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TRV027

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Imperial College London

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2020

              Details:

              Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19.

              Renibus Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association

              Contact the Supplier

              Lead Product(s): Sucroferric Oxyhydroxide,Stannous protoporphyrin

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2020

              Details:

              Based on the results to be presented at ERA-EDTA, the company is currently planning a Phase 2 study to investigate whether RBT-1 upregulates the expression of these biomarkers of cytoprotection in patients scheduled to undergo cardiac surgery.

              PharmaCompass__DigitalAd